07:00 , Jun 13, 2011 |  BioCentury  |  Finance

Ambit's gambit

The day after cancer play Ambit Biosciences Corp. withdrew an IPO, it revealed that existing investors had ponied up $30 million in a series D-2 round. That took the mystery out of its SEC filing...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Clinical News

AC430: Phase I started

Ambit began a placebo-controlled Phase I trial to evaluate single- and multiple-ascending doses of oral AC430 in healthy volunteers. Ambit Biosciences Corp. , San Diego, Calif.   Product: AC430 ( BMS-599626 )   Business: Autoimmune,...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Clinical News

AC480: Phase I started

Ambit began an open-label, dose-escalation Phase I trial to evaluate IV AC480 given on the first 2 days of a 21-day cycle with or without Taxotere docetaxel in 100 patients. Ambit licensed AC480 from Bristol-Myers....